Role and therapeutic potential of Glycodelin A in systemic lupus erythematosus.
Glycodelin A (GdA) is a lipocalin with an immunomodulatory role. Low expression of GdA has been implicated in the progression of autoimmune disease. Therefore, strategies targeting GdA may constitute an important target for the design of drugs for autoimmune disease including systemic lupus erythematosus (SLE). This opinion article will focus on current understanding of the role of GdA in the physiological and pathological functions associated with SLE. It is the intention of the article to provide insights that may assist in the development of GdA-based approaches for the treatment of SLE.
Department of Epidemiology and Biostatistics, Anhui Medical University, Anhui, People's Republic of China.
Hai-Feng
HF
Pan
Rui-Xue
RX
Leng
Ning
N
Zhang
Jin-Hui
JH
Tao
Dong-Qing
DQ
Ye
D000818:Animals; D015551:Autoimmunity / Q000187:drug effects; D000071816:Glycodelin; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism*; D011257:Pregnancy Proteins / Q000378:metabolism*; D017634:Self Tolerance / Q000187:drug effects
D000071816:Glycodelin; D006023:Glycoproteins; D007166:Immunosuppressive Agents; C045246:PAEP protein, human; D011257:Pregnancy Proteins